Essity launches review of Vinda, Consumer Tissue Private Label Europe business

Essity initiates strategic review of stake in China-based Vinda and Consumer Tissue Private Label Europe business.

Hygiene company Essity has initiated a strategic review of its stake in China-based Vinda and its Consumer Tissue Private Label Europe business.

According to the company, the strategic review includes “exploring different options and may result in divestments, although no such decisions have yet been taken”.

“Essity continuously evaluates the product portfolios within the company’s three business areas, health and medical, consumer goods, and professional hygiene, to achieve increased long-term value creation,” the company said in a statement.

In 2022, Vinda accounted for approximately 16 per cent of Essity’s net sales for 2022 and the Consumer Tissue Private Label Europe business approximately 6 per cent.

Vinda and the Consumer Tissue Private Label Europe business accounted for approximately 34 per cent of the business area consumer goods net sales 2022 and approximately 45 per cent of the consumer tissue category net sales in 2022.

Essity’s ownership in Vinda amounts to 51.59 per cent and Essity consolidates 100 per cent.

Comment below to have your say on this story.

If you have a news story or tip-off, get in touch at info@incleanmag.co.nz

Sign up to INCLEAN NZ’s newsletter.

TAGS

Leave a comment:

Your email address will not be published. All fields are required